Raymond James Financial Services Advisors Inc. Has $82,000 Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Raymond James Financial Services Advisors Inc. lifted its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 61.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 48,309 shares of the biotechnology company’s stock after acquiring an additional 18,333 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Heron Therapeutics were worth $82,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. SG Americas Securities LLC acquired a new stake in Heron Therapeutics during the third quarter worth about $31,000. Dakota Wealth Management acquired a new stake in Heron Therapeutics during the third quarter worth about $55,000. Apeiron RIA LLC grew its stake in Heron Therapeutics by 59.6% during the third quarter. Apeiron RIA LLC now owns 83,000 shares of the biotechnology company’s stock worth $85,000 after buying an additional 31,000 shares in the last quarter. Richmond Brothers Inc. grew its stake in Heron Therapeutics by 142.9% during the third quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock worth $106,000 after buying an additional 60,604 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in Heron Therapeutics by 5.5% during the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock worth $324,000 after buying an additional 16,467 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Thursday, April 11th. Capital One Financial began coverage on shares of Heron Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $6.00 price objective on the stock. Finally, StockNews.com upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th.

Heron Therapeutics Trading Down 3.8 %

HRTX opened at $2.55 on Friday. The company’s 50 day moving average is $2.75 and its 200-day moving average is $1.96. Heron Therapeutics, Inc. has a 1-year low of $0.50 and a 1-year high of $3.22. The company has a market cap of $383.34 million, a P/E ratio of -2.97 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The business had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million. On average, equities analysts forecast that Heron Therapeutics, Inc. will post -0.22 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.